— Know what they know.
Not Investment Advice

HMD.AX ASX

HeraMED Limited
1W: -6.7% 1M: +16.7% 3M: +0.0% YTD: +5.0% 1Y: +23.5% 3Y: -38.7% 5Y: -78.5%
A$0.04 ($0.03)
+0.00 (+0.00%)
 
Weekly Expected Move ±12.8%
A$0 A$0 A$0 A$0 A$0
ASX · Healthcare · Medical - Devices · Tech Score Neutral · Power 58 · A$48.7M mcap · 1.13B float · 0.074% daily turnover
Smart Money Score
No convergence signal
Key Statistics
Market CapA$48.7M ($33.8M)
52W Range0.03-0.055
Volume92,871
Avg Volume834,532
Beta0.05
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOAnoushka Gungadin
Employees6
SectorHealthcare
IndustryMedical - Devices
IPO Date2018-12-11
117 Camberwell Road
Hawthorn East, VIC 3123
AU
+972 9 833 3693
About HeraMED Limited

HeraMED Limited and its associated entities are dedicated to the design, production, and sale of at-home fetal heart rate monitors and comprehensive pregnancy monitoring systems. These solutions are offered to consumers throughout Australia, Europe, and Israel. Key products include HeraBEAT, a device enabling expectant mothers to personally track their baby's heartbeat, and HeraCARE, a sophisticated digital platform facilitating the creation and deployment of health solutions for effective maternity care management. The company is also at the forefront of developing EchoBEAT, envisioned as the subsequent evolution of its domestic pregnancy monitoring tools, alongside Orion, an artificial intelligence-driven system engineered for profound pregnancy monitoring analysis. A strategic partnership with Mayo Clinic supports the ongoing advancement of the HeraCARE pregnancy management platform. Established in 2011, HeraMED Limited operates from its main office in Netanya, Israel.

Latest News
No recent news

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms